VanEck Biotech ETF (NASDAQ:BBH) Major Shareholder Sardar Biglari Sells 11,000 Shares

VanEck Biotech ETF (NASDAQ:BBH) major shareholder Sardar Biglari sold 11,000 shares of the stock in a transaction that occurred on Friday, July 17th. The stock was sold at an average price of $16.71, for a total transaction of $183,810.00. Following the completion of the transaction, the insider owned 3,538,961 shares in the company, valued at $59,136,038.31. This trade represents a 0.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Sardar Biglari also recently made the following trade(s):

• On Thursday, July 16th, Sardar Biglari sold 2,749 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.70, for a total transaction of $45,908.30.
• On Wednesday, July 15th, Sardar Biglari sold 6,533 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.71, for a total transaction of $109,166.43.
• On Tuesday, July 14th, Sardar Biglari sold 1,211 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.73, for a total transaction of $20,260.03.

VanEck Biotech ETF Trading Up 0.6%

BBH opened at $203.43 on Wednesday. VanEck Biotech ETF has a 1-year low of $155.45 and a 1-year high of $212.54. The firm’s 50 day simple moving average is $193.71 and its two-hundred day simple moving average is $192.14.

Institutional Investors Weigh In On VanEck Biotech ETF

Hedge funds and other institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. lifted its position in VanEck Biotech ETF by 40,463.3% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 494,061 shares of the company’s stock valued at $93,506,000 after purchasing an additional 492,843 shares in the last quarter. Raymond James Financial Inc. grew its holdings in VanEck Biotech ETF by 2.8% during the third quarter. Raymond James Financial Inc. now owns 69,809 shares of the company’s stock valued at $11,566,000 after purchasing an additional 1,869 shares during the period. Bank of America Corp DE increased its position in VanEck Biotech ETF by 44.3% in the first quarter. Bank of America Corp DE now owns 66,338 shares of the company’s stock worth $12,473,000 after buying an additional 20,375 shares in the last quarter. Ascent Advisors LLC purchased a new stake in VanEck Biotech ETF in the first quarter worth about $11,178,000. Finally, LPL Financial LLC increased its position in VanEck Biotech ETF by 63.5% in the fourth quarter. LPL Financial LLC now owns 31,813 shares of the company’s stock worth $6,021,000 after buying an additional 12,351 shares in the last quarter. 32.05% of the stock is currently owned by hedge funds and other institutional investors.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.